research Treatment of alopecia areata in pre‐adolescent children with oral tofacitinib: A retrospective study
Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
Search
for
Sort by
Research
510-540 / 1000+ results 
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Combination tofacitinib and oral minoxidil treatment for severe alopecia areata
Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
research Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
Dupilumab helps children with alopecia areata regrow hair safely.
research Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata
Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.
research Cardiodermatology: the heart of the connection between the skin and cardiovascular disease
Skin conditions can signal heart issues, highlighting the need for integrated care.
research Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
research Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib
Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
research Case report of novel combination of anthralin and calcipotriene leading to trichologic response in alopecia areata
A new mix of anthralin and calcipotriene might help treat severe hair loss.
research The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
research Drug-Induced Alopecia Areata From Upadacitinib
Upadacitinib may cause hair loss.
research Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
research Lokivetmab improved pruritus in a dog with cutaneous epitheliotropic lymphoma
Lokivetmab reduced itching in a dog with skin lymphoma.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research Combining 308-monochromatic excimer phototherapy with monthly IM triamcinolone acetonide for the treatment of resistant alopecia totalis
The combination therapy was effective and well-tolerated, especially in young patients.
research Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy
Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
research 1322 Molecular profiling of frontal fibrosing alopecia (FFA) reveals TH1 and JAK-STAT up-regulation with no suppression of hair keratins
Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.
research Practice and Educational Gaps in Dermatology
Dermatologists often neglect hair disorders due to complexity and lack of clear treatments, impacting patient care and highlighting the need for better education and interest in this area.
research Current and future pharmacotherapy for alopecia areata
New treatments for hair loss show promise but need more research to confirm safety and effectiveness.
research Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
research Upadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review
Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Mechanism of PPARα agonist in alopecia areata
PPARα agonists may help treat alopecia areata by reducing inflammation.
research Enhanced Insights into Frontal Fibrosing Alopecia: Advancements in Pathogenesis Understanding and Management Strategies
Frontal Fibrosing Alopecia needs better diagnostics and treatments, with dutasteride showing promise.
research Efficacy of systemic minoxidil and tofacitinib combination in treatment‐resistant alopecia universalis
Using minoxidil and tofacitinib together can effectively treat severe hair loss.
research Alopecia universalis treated with simvastatin/ezetimibe, minoxidil, and prednisolone in a 6‐year‐old girl
A 6-year-old girl with alopecia universalis regrew most of her hair after treatment with simvastatin/ezetimibe, minoxidil, and prednisolone.